• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

johnsonandjohnson

Johnson & Johnson sees global pharma sales climb 20% in Q2

July 17, 2018 By Sarah Faulkner

Johnson & Johnson

Healthcare giant Johnson & Johnson (NYSE:JNJ) today topped sales and earnings estimates with its second-quarter financial results, posting sales growth of 19.9% for its pharmaceutical segment compared to the same period last year. The New Brunswick, N.J.-based company reported overall profit growth of 3.1% to $3.95 billion, or $1.45 per share, on sales of $20.83 billion […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson

CeQur acquires wearable insulin delivery device

July 17, 2018 By Sarah Faulkner

CeQur Calibra insulin delivery device

CeQur said today that it acquired a wearable, on-demand insulin delivery system from Johnson & Johnson‘s (NYSE:JNJ) Calibra Medical for an undisclosed amount. The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: cequr, johnsonandjohnson

Johnson & Johnson OKs $2B LifeScan sale to Platinum Equity

June 12, 2018 By Brad Perriello

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) said today that it accepted a binding offer of more than $2 billion from private equity shop Platinum Equity for its LifeScan blood glucose monitoring business as it moves toward the exit in the diabetes market. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, […]

Filed Under: Diabetes, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: johnsonandjohnson, lifescan

J&J’s Janssen touts Ph3 data for antidepressant nasal spray

May 7, 2018 By Sarah Faulkner

Janssen

Johnson & Johnson‘s (NYSE:JNJ) Janssen revealed data today from two Phase III trials of its investigational esketamine nasal spray in patients with treatment-resistant depression. The Titusville, N.J.-based company said that if approved by the FDA, esketamine would represent one of the first new approaches designed to treat refractory major depressive disorder in the last 50 […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: janssen, johnsonandjohnson

J&J’s Janssen acquires cancer-killing virus tech

May 2, 2018 By Sarah Faulkner

Janssen

Johnson & Johnson‘s (NYSE:JNJ) Janssen Biotech said today that it agreed to acquire BeneVir Biopharm and its T-Stealth oncolytic virus platform. The privately-held biopharmaceutical company engineers cancer-killing viruses that are designed to infect and destroy cancer cells. Janssen plans to develop BeneVir’s preclinical candidates for the treatment of solid tumor cancers. According to the terms […]

Filed Under: Featured, Immunotherapy, Mergers & Acquisitions, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: janssen, johnsonandjohnson

Report: J&J’s Cerenovus to discontinue Codman liver cancer pump

April 26, 2018 By Fink Densford

Johnson & Johnson

Johnson & Johnson‘s (NYSE:JNJ) Cerenovus is discontinuing production of its Codman pumps designed to deliver targeted chemotherapy to the liver for patients with liver cancer, according to a New York Times report. The devices are designed to be implanted in the abdomen to deliver chemotherapy directly to the liver to treat cancer that has spread […]

Filed Under: Featured, Implants, Oncology Tagged With: johnsonandjohnson, Medtronic

Johnson & Johnson’s global pharma sales up 19% in Q1

April 17, 2018 By Sarah Faulkner

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) today reported first-quarter sales and earnings results, topping analysts’ expectations on Wall Street. The company’s pharmaceutical business delivered “robust growth,” chairman & CEO Alex Gorsky said in a statement; worldwide global sales grew 19.4% to $9.8 billion for the first quarter compared to same period in 2017. Domestic sales were up […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson

Medtech stories we missed this week: April 6, 2018

April 6, 2018 By Danielle Kirsh

missed-medtech-0406

From CHF Solutions’s distribution deal to Guided Therapeutics’s licensing agreement, here are seven medtech stories we missed this week but throught were still worth mentioning. 1. CHF inks Spanish distribution deal CHF Solutions announced in an April 5 press release that it has signed a distribution agreement with Dimedix Surgical. The distribution agreement will allow […]

Filed Under: Featured, Food & Drug Administration (FDA), Hospital Care, Imaging, Implants, Regulatory/Compliance Tagged With: asahiintecc, aziyobiologics, Biotronik, chfsolutions, Guided Therapeutics, hypermed, instrumedsurgical, johnsonandjohnson, medtech, NanoVibronix

Johnson & Johnson moves closer to exiting the diabetes business with $2.1B LifeScan sale

March 16, 2018 By Brad Perriello

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) took another step toward the exit door for the diabetes business, agreeing to a $2,1 billion offer from private equity shop Platinum Equity for its LifeScan blood glucose monitoring unit. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later […]

Filed Under: Diabetes, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: johnsonandjohnson, lifescan

Pharma revenue drives Johnson & Johnson’s Q4 beat

January 24, 2018 By Sarah Faulkner

Johnson & Johnson

Shares in Johnson & Johnson (NYSE:JNJ) fell yesterday after the healthcare giant topped Wall Street’s expectations for fourth-quarter results but missed analysts’ forecast for the full-year. Despite taking a $13.6 billion hit to its unremitted foreign earnings thanks to new efforts to reform the U.S. tax system, the company said it is pleased with the legislation […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS